Amylin (AMLN) Shares Jump 14% Amid BYDUREON Recommendation for Approval in Europe
Tweet
Share
E-mailGet Alerts AMLN Hot Sheet
Join SI Premium – FREE
Shares of Amylin (Nasdaq: AMLN) are up nearly 14% in pre-market action following news that BYDUREON was recommended for approval in Europe.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Milestone Pharmaceuticals starts Phase 3 AFib-RVR trial for etripamil
- Harrow study shows Iheezo cuts discomfort after eye injections
- Trans Canada Gold completes phase 1 drilling at Harrison Lake project
Create E-mail Alert Related Categories
FDA, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
